Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Moreover, Novo Nordisk also claims that it is difficult to manufacture liraglutide and "even small changes in the manufacturing process of ... made a similar case for semaglutide in a petition ...

The deal adds to a rapidly-expanding pipeline of NASH candidates at Novo Nordisk, which also includes GLP-1 analogue semaglutide in ... ZyVersa is in the process of going public via a merger ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...

We came across a bullish thesis on Novo Nordisk A/S (NVO ... despite facing short-term headwinds in the U.S. from compounded semaglutide alternatives, is expected to rebound strongly through ...

Novo Nordisk has a strong economic moat based on significant market shares in diabetes and obesity care, and promising pipeline drugs, though facing competition and political pressures.

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO ...

Novo Nordisk (NYSE:NVO) shares dropped 5% in early trading on Monday after Eli Lilly (NYSE:LLY) released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy.

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's ... said a trial with higher dose of semaglutide this year showed greater ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more ...